Intravitreal tissue plasminogen activator for the treatment of central retinal vein occlusion

Ophthalmic Surg Lasers Imaging. 2003 Jul-Aug;34(4):350-2.

Abstract

A 58-year-old hypertensive man with a perfused central retinal vein occlusion of 21 days' duration received 50 microg of intravitreal recombinant tissue plasminogen activator in 0.1 cc. Best-corrected visual acuity improved 2 weeks after the injection. Optical coherence tomography and fluorescein angiography demonstrated resolution of cystoid macular edema and improvement of venous outflow. Intravitreal tissue plasminogen activator may be a useful treatment for central retinal vein occlusion with a duration of 21 days or less.

Publication types

  • Case Reports

MeSH terms

  • Fluorescein Angiography
  • Fundus Oculi
  • Humans
  • Macular Edema / complications
  • Male
  • Middle Aged
  • Ophthalmoscopy
  • Optics and Photonics
  • Retinal Vein Occlusion / complications
  • Retinal Vein Occlusion / diagnosis
  • Retinal Vein Occlusion / drug therapy*
  • Retinal Vein Occlusion / physiopathology
  • Tissue Plasminogen Activator / administration & dosage*
  • Tomography
  • Visual Acuity
  • Vitreous Body

Substances

  • Tissue Plasminogen Activator